Drug Delivery Technologies Market (Metered Dose Inhalers, Needle-Free Injectors, Auto-Injectors, Nasal Sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) - Global Forecasts To 2017
The drug delivery technology market is segmented on the basis of route of administration into nine categories - oral, pulmonary, transdermal, injectable, ocular, nasal, topical, implantable, and transmucosal drug delivery; the market is forecast till 2017. Over the years, drug delivery technologies have grown phenomenally from plain drug reformulation and release technologies to innovative platforms that hold a huge potential for the effective delivery of biologicals and novel drugs.
The global drug delivery market was worth $142.5 billion in the year 2012. Patent expiries of certain blockbuster drugs, growing demand for self administration and home healthcare devices, rising incidence of chronic diseases such as cardiovascular diseases, diabetes and cancer, growing focus on pediatric and geriatric patients, and advancing technology are accelerating the growth of this market. However, drug failures and recalls, and technical barriers will hamper the growth of this market, to a certain extent.
Strategic collaborations, self administration and home care drug delivery devices, and expanding applications of drug delivery into niche therapeutic areas represent vast opportunities for key players in this market. The growing number of elderly persons is a large consumer of home care drug delivery devices. The global ageing population (above 60 years) is set to increase from 784 million in 2011 to 2 billion by 2050 and 2.8 billion by 2100. (Source: UN Population Division). An increase in the number of geriatric patients and rise in demand for convenient drug delivery options pose major opportunities for the development of innovative and easy-to-use drug delivery systems.
Striking right partnership deal and enhancing the bioavailability of drugs are some of the burning issues in this market. In spite of a large number of strategic collaborations taking place every year, pharmaceutical and biotechnology companies are facing problems in finding a right drug delivery partner. Considering this need, a number of national and international conferences are organized by various associations and organizations to facilitate drug delivery partnerships.
The geographies covered in this study are North America, Europe, Asia and Rest of the world (RoW). North America is the largest market for drug delivery, followed by Europe and Asia. North America and Europe are expected to grow at a slower pace, primarily due to a certain amount of saturation in the market. The Asian market is poised to register maximum growth over the next five years, owing to the expansion of Asian economy, increase in disposable income, development of healthcare infrastructure, increasing penetration of health insurance, and rising prevalence of chronic diseases.
Scope of the Report
This research report categorizes the global drug delivery market into oral, pulmonary, transdermal, injectable, ocular, nasal, topical, implantable, and transmucosal drug delivery. These markets are broken down into segments and sub-segments, providing exhaustive value analysis for 2010, 2011 and 2012, as well as forecast up to 2017. Each of the drug delivery market is comprehensively analyzed at a granular level by geography (North America, Europe, Asia, and Rest of the World) to provide in-depth information on the global scenario.
Global drug delivery market, by route of administration
The global drug delivery market was worth $142.5 billion in the year 2012. Patent expiries of certain blockbuster drugs, growing demand for self administration and home healthcare devices, rising incidence of chronic diseases such as cardiovascular diseases, diabetes and cancer, growing focus on pediatric and geriatric patients, and advancing technology are accelerating the growth of this market. However, drug failures and recalls, and technical barriers will hamper the growth of this market, to a certain extent.
Strategic collaborations, self administration and home care drug delivery devices, and expanding applications of drug delivery into niche therapeutic areas represent vast opportunities for key players in this market. The growing number of elderly persons is a large consumer of home care drug delivery devices. The global ageing population (above 60 years) is set to increase from 784 million in 2011 to 2 billion by 2050 and 2.8 billion by 2100. (Source: UN Population Division). An increase in the number of geriatric patients and rise in demand for convenient drug delivery options pose major opportunities for the development of innovative and easy-to-use drug delivery systems.
Striking right partnership deal and enhancing the bioavailability of drugs are some of the burning issues in this market. In spite of a large number of strategic collaborations taking place every year, pharmaceutical and biotechnology companies are facing problems in finding a right drug delivery partner. Considering this need, a number of national and international conferences are organized by various associations and organizations to facilitate drug delivery partnerships.
The geographies covered in this study are North America, Europe, Asia and Rest of the world (RoW). North America is the largest market for drug delivery, followed by Europe and Asia. North America and Europe are expected to grow at a slower pace, primarily due to a certain amount of saturation in the market. The Asian market is poised to register maximum growth over the next five years, owing to the expansion of Asian economy, increase in disposable income, development of healthcare infrastructure, increasing penetration of health insurance, and rising prevalence of chronic diseases.
Scope of the Report
This research report categorizes the global drug delivery market into oral, pulmonary, transdermal, injectable, ocular, nasal, topical, implantable, and transmucosal drug delivery. These markets are broken down into segments and sub-segments, providing exhaustive value analysis for 2010, 2011 and 2012, as well as forecast up to 2017. Each of the drug delivery market is comprehensively analyzed at a granular level by geography (North America, Europe, Asia, and Rest of the World) to provide in-depth information on the global scenario.
Global drug delivery market, by route of administration
- Oral
- Controlled Release
- Orodispersible Tablets (ODT) and Taste Masking
- Others
- Pulmonary
- Dry Powder Inhalers
- Metered Dose Inhalers
- Nebulizers
- Transdermal
- Passive
- Reservoir System
- Matrix System
- Active
- Iontophoresis
- Microporation
- Others
- Injectable
- Conventional Injection Devices
- Fillable Syringes
- Prefilled Syringes
- Self-injection Devices
- Needle-free Injectors
- Auto-injectors or Safety Syringe Devices
- Pen Injectors
- Others
- Ocular
- Eye Drops
- Ointment and Gel
- Others
- Nasal
- Nasal Drops
- Nasal Sprays
- Nasal Inhalers
- Others
- Topical
- Liquid Formulations
- Semi-solid Formulations
- Solid Formulations
- Implantable
- Drug Eluting Stents
- Implantable Infusion Pumps
- Intravitreal Implants
- Brachytherapy Seeds
- Contraceptive Implants
- Transmucosal
- Oral (Buccal and Sublingual)
- Others (Rectal and Vaginal)
- North America
- Europe
- Asia
- Rest of the World (RoW)
1 INTRODUCTION
1.1 KEY TAKE-AWAYS
1.2 REPORT DESCRIPTION
1.3 MARKETS COVERED
1.4 STAKEHOLDERS
1.5 RESEARCH METHODOLOGY
1.5.1 MARKET SIZE
1.5.2 MARKET SHARE
1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES
1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES
1.5.5 ASSUMPTIONS
2 EXECUTIVE SUMMARY
3 MARKET OVERVIEW
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 MARKET DYNAMICS
3.3.1 DRIVERS
3.3.1.1 Patent cliff and increased competition to increase adoption rate
3.3.1.2 Improving patient compliance and acceptability, an impetus to the drug delivery systems market
3.3.1.3 Increasing focus on pediatric and geriatric patients to boost the growth
3.3.1.4 Increasing incidence of chronic diseases to enhance demand
3.3.2 RESTRAINTS
3.3.2.1 Drug failures and recalls mar market growth
3.3.2.2 Technical barriers restrict growth
3.3.3 OPPORTUNITIES
3.3.3.1 Collaborations between pharmaceutical companies and drug delivery firms
3.3.3.2 Self-administration and home care drug delivery devices
3.3.3.3 Expanding therapeutic applications of drug delivery technologies
3.3.4 TARGETED DRUG DELIVERY
3.3.4.1 Passive systems contribute 60% to the targeted drug delivery market
3.3.4.2 Active targeted drug delivery has major applications in cancer therapy
3.3.4.3 Companies focus on novel targeted drug delivery
3.3.5 BURNING ISSUES
3.3.5.1 Striking right partnerships
3.3.5.2 Improving the bioavailability of drugs
3.4 REGULATORY ENVIRONMENT
3.4.1 STRINGENT REGULATIONS FOR PHARMACEUTICAL DRUGS ACROSS THE GLOBE
3.4.1.1 The approval process is complex, time-consuming, and expensive
3.4.2 EFFECT OF THE U.S. HEALTHCARE REFORMS ON THE DRUG DELIVERY INDUSTRY
3.4.3 REGULATIONS RELATED TO THE APPROVAL OF CONTROLLED RELEASE DRUGS
3.5 PORTER’S FIVE FORCES ANALYSIS
3.6 VALUE CHAIN ANALYSIS
3.7 MARKET SHARE ANALYSIS
3.7.1 PULMONARY DRUG DELIVERY
3.7.2 TRANSDERMAL DRUG DELIVERY
3.7.3 INJECTABLE DRUG DELIVERY
3.7.3.1 Conventional injection devices
3.7.3.2 Self-injection devices
3.7.4 IMPLANTABLE DRUG DELIVERY
3.7.5 OTHER DRUG DELIVERY SEGMENTS
4 GLOBAL DRUG DELIVERY MARKET, BY TECHNOLOGY
4.1 INTRODUCTION
4.1.1 DRUG DELIVERY MARKET WITNESSING TECHNOLOGICAL ADVANCEMENTS
4.2 OPPORTUNITY MATRIX
4.3 ORAL DRUG DELIVERY
4.3.1 BIG PHARMA COMPANIES ESTABLISHING IN-HOUSE CAPABILITIES
4.3.2 CONTROLLED RELEASE
4.3.3 ORODISPERSIBLE TABLETS (ODT) AND TASTE MASKING
4.3.4 OTHERS
4.4 PULMONARY DRUG DELIVERY
4.4.1 THERAPEUTIC APPLICATIONS OF PULMONARY DELIVERY
4.4.1.1 Application of pulmonary delivery for non-respiratory therapies is a growing opportunity
4.4.2 METERED DOSE INHALERS (MDI)
4.4.3 DRY POWDER INHALERS (DPI)
4.4.4 NEBULIZERS
4.5 TRANSDERMAL DRUG DELIVERY
4.5.1 PASSIVE TRANSDERMAL DRUG DELIVERY
4.5.1.1 Matrix system
4.5.1.2 Reservoir system
4.5.2 ACTIVE TRANSDERMAL DRUG DELIVERY
4.5.2.1 Microporation
4.5.2.2 Iontophoresis
4.5.2.3 Others
4.6 INJECTABLE DRUG DELIVERY
4.6.1 INJECTABLE DRUG DELIVERY MARKET WITNESSING DEVELOPMENTS RELATED TO PRODUCT IMPROVEMENT
4.6.2 CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES
4.6.2.1 Low manufacturing cost and affordable prices: key driver for conventional injection devices
4.6.2.2 Fillable
4.6.2.3 Prefilled
4.6.3 SELF-INJECTION DEVICES
4.6.3.1 Self-injection devices reduce overall treatment cost
4.6.3.2 Pen injectors
4.6.3.3 Needle-free injectors
4.6.3.4 Auto injectors
4.6.4 OTHERS
4.7 OCULAR DRUG DELIVERY
4.7.1 EYE DROPS
4.7.2 OINTMENTS AND GELS
4.7.3 OTHERS
4.8 NASAL DRUG DELIVERY
4.8.1 NASAL DRUG DELIVERY PREFERRED FOR LOCALLY ACTING DRUGS AND DELIVERY OF VACCINES
4.8.2 NASAL SPRAYS
4.8.3 NASAL INHALERS
4.8.4 NASAL DROPS
4.8.5 OTHERS
4.9 TOPICAL DRUG DELIVERY
4.9.1 TOPICAL DELIVERY MAJORLY ADOPTED FOR DERMATOLOGY DRUGS
4.9.2 SEMI-SOLID FORMULATIONS
4.9.3 LIQUID FORMULATIONS
4.9.4 SOLID FORMULATIONS
4.10 IMPLANTABLE DRUG DELIVERY
4.10.1 DRUG- ELUTING STENTS
4.10.2 IMPLANTABLE INFUSION PUMPS
4.10.2.1 Implantable infusion pumps largely used for therapies of chronic ailments
4.10.3 CONTRACEPTIVE IMPLANTS
4.10.4 INTRAVITREAL IMPLANTS
4.10.5 BRACHYTHERAPY SEEDS
4.11 TRANSMUCOSAL DRUG DELIVERY
4.11.1 ORAL (BUCCAL AND SUBLINGUAL)
4.11.2 OTHERS (RECTAL, VAGINAL)
5 GEOGRAPHIC ANALYSIS
5.1 INTRODUCTION
5.2 NORTH AMERICA
5.2.1 HEALTHCARE REFORMS IN THE U.S. WILL IMPACT THE DRUG DELIVERY MARKET
5.3 EUROPE
5.4 ASIA
5.4.1 BOOMING PHARMACEUTICAL INDUSTRY SET TO ACCELERATE THE GROWTH
5.5 REST OF THE WORLD (ROW)
6 COMPETITIVE LANDSCAPE
6.1 INTRODUCTION
6.2 MERGERS & ACQUISITIONS
6.3 AGREEMENTS, COLLABORATIONS, JOINT VENTURES & PARTNERSHIPS
6.4 NEW PRODUCT LAUNCH
6.5 OTHER DEVELOPMENTS
7 COMPANY PROFILES (OVERVIEW, FINANCIALS, PRODUCTS & SERVICES, STRATEGY, & DEVELOPMENTS)
7.1 3M COMPANY
7.2 ALKERMES, INC.
7.3 APTALIS PHARMA, INC.
7.4 BAXTER INTERNATIONAL, INC.
7.5 BECTON, DICKINSON AND COMPANY
7.6 CATALENT PHARMA SOLUTIONS
7.7 CIMA LABS
7.8 DALI MEDICAL DEVICES
7.9 ENDO HEALTH SOLUTIONS, INC.
7.10 FOAMIX
7.11 JOHNSON & JOHNSON, INC.
7.12 NEKTAR THERAPEUTICS, INC.
7.13 OPTINOSE AS
7.14 PSIVIDA CORPORATION
7.15 SKYEPHARMA PLC
7.16 TAPEMARK
7.17 THE DOW CHEMICAL COMPANY
7.18 VALEANT PHARMACEUTICALS
7.19 YPSOMED HOLDING AG (Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.)
1.1 KEY TAKE-AWAYS
1.2 REPORT DESCRIPTION
1.3 MARKETS COVERED
1.4 STAKEHOLDERS
1.5 RESEARCH METHODOLOGY
1.5.1 MARKET SIZE
1.5.2 MARKET SHARE
1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES
1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES
1.5.5 ASSUMPTIONS
2 EXECUTIVE SUMMARY
3 MARKET OVERVIEW
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 MARKET DYNAMICS
3.3.1 DRIVERS
3.3.1.1 Patent cliff and increased competition to increase adoption rate
3.3.1.2 Improving patient compliance and acceptability, an impetus to the drug delivery systems market
3.3.1.3 Increasing focus on pediatric and geriatric patients to boost the growth
3.3.1.4 Increasing incidence of chronic diseases to enhance demand
3.3.2 RESTRAINTS
3.3.2.1 Drug failures and recalls mar market growth
3.3.2.2 Technical barriers restrict growth
3.3.3 OPPORTUNITIES
3.3.3.1 Collaborations between pharmaceutical companies and drug delivery firms
3.3.3.2 Self-administration and home care drug delivery devices
3.3.3.3 Expanding therapeutic applications of drug delivery technologies
3.3.4 TARGETED DRUG DELIVERY
3.3.4.1 Passive systems contribute 60% to the targeted drug delivery market
3.3.4.2 Active targeted drug delivery has major applications in cancer therapy
3.3.4.3 Companies focus on novel targeted drug delivery
3.3.5 BURNING ISSUES
3.3.5.1 Striking right partnerships
3.3.5.2 Improving the bioavailability of drugs
3.4 REGULATORY ENVIRONMENT
3.4.1 STRINGENT REGULATIONS FOR PHARMACEUTICAL DRUGS ACROSS THE GLOBE
3.4.1.1 The approval process is complex, time-consuming, and expensive
3.4.2 EFFECT OF THE U.S. HEALTHCARE REFORMS ON THE DRUG DELIVERY INDUSTRY
3.4.3 REGULATIONS RELATED TO THE APPROVAL OF CONTROLLED RELEASE DRUGS
3.5 PORTER’S FIVE FORCES ANALYSIS
3.6 VALUE CHAIN ANALYSIS
3.7 MARKET SHARE ANALYSIS
3.7.1 PULMONARY DRUG DELIVERY
3.7.2 TRANSDERMAL DRUG DELIVERY
3.7.3 INJECTABLE DRUG DELIVERY
3.7.3.1 Conventional injection devices
3.7.3.2 Self-injection devices
3.7.4 IMPLANTABLE DRUG DELIVERY
3.7.5 OTHER DRUG DELIVERY SEGMENTS
4 GLOBAL DRUG DELIVERY MARKET, BY TECHNOLOGY
4.1 INTRODUCTION
4.1.1 DRUG DELIVERY MARKET WITNESSING TECHNOLOGICAL ADVANCEMENTS
4.2 OPPORTUNITY MATRIX
4.3 ORAL DRUG DELIVERY
4.3.1 BIG PHARMA COMPANIES ESTABLISHING IN-HOUSE CAPABILITIES
4.3.2 CONTROLLED RELEASE
4.3.3 ORODISPERSIBLE TABLETS (ODT) AND TASTE MASKING
4.3.4 OTHERS
4.4 PULMONARY DRUG DELIVERY
4.4.1 THERAPEUTIC APPLICATIONS OF PULMONARY DELIVERY
4.4.1.1 Application of pulmonary delivery for non-respiratory therapies is a growing opportunity
4.4.2 METERED DOSE INHALERS (MDI)
4.4.3 DRY POWDER INHALERS (DPI)
4.4.4 NEBULIZERS
4.5 TRANSDERMAL DRUG DELIVERY
4.5.1 PASSIVE TRANSDERMAL DRUG DELIVERY
4.5.1.1 Matrix system
4.5.1.2 Reservoir system
4.5.2 ACTIVE TRANSDERMAL DRUG DELIVERY
4.5.2.1 Microporation
4.5.2.2 Iontophoresis
4.5.2.3 Others
4.6 INJECTABLE DRUG DELIVERY
4.6.1 INJECTABLE DRUG DELIVERY MARKET WITNESSING DEVELOPMENTS RELATED TO PRODUCT IMPROVEMENT
4.6.2 CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES
4.6.2.1 Low manufacturing cost and affordable prices: key driver for conventional injection devices
4.6.2.2 Fillable
4.6.2.3 Prefilled
4.6.3 SELF-INJECTION DEVICES
4.6.3.1 Self-injection devices reduce overall treatment cost
4.6.3.2 Pen injectors
4.6.3.3 Needle-free injectors
4.6.3.4 Auto injectors
4.6.4 OTHERS
4.7 OCULAR DRUG DELIVERY
4.7.1 EYE DROPS
4.7.2 OINTMENTS AND GELS
4.7.3 OTHERS
4.8 NASAL DRUG DELIVERY
4.8.1 NASAL DRUG DELIVERY PREFERRED FOR LOCALLY ACTING DRUGS AND DELIVERY OF VACCINES
4.8.2 NASAL SPRAYS
4.8.3 NASAL INHALERS
4.8.4 NASAL DROPS
4.8.5 OTHERS
4.9 TOPICAL DRUG DELIVERY
4.9.1 TOPICAL DELIVERY MAJORLY ADOPTED FOR DERMATOLOGY DRUGS
4.9.2 SEMI-SOLID FORMULATIONS
4.9.3 LIQUID FORMULATIONS
4.9.4 SOLID FORMULATIONS
4.10 IMPLANTABLE DRUG DELIVERY
4.10.1 DRUG- ELUTING STENTS
4.10.2 IMPLANTABLE INFUSION PUMPS
4.10.2.1 Implantable infusion pumps largely used for therapies of chronic ailments
4.10.3 CONTRACEPTIVE IMPLANTS
4.10.4 INTRAVITREAL IMPLANTS
4.10.5 BRACHYTHERAPY SEEDS
4.11 TRANSMUCOSAL DRUG DELIVERY
4.11.1 ORAL (BUCCAL AND SUBLINGUAL)
4.11.2 OTHERS (RECTAL, VAGINAL)
5 GEOGRAPHIC ANALYSIS
5.1 INTRODUCTION
5.2 NORTH AMERICA
5.2.1 HEALTHCARE REFORMS IN THE U.S. WILL IMPACT THE DRUG DELIVERY MARKET
5.3 EUROPE
5.4 ASIA
5.4.1 BOOMING PHARMACEUTICAL INDUSTRY SET TO ACCELERATE THE GROWTH
5.5 REST OF THE WORLD (ROW)
6 COMPETITIVE LANDSCAPE
6.1 INTRODUCTION
6.2 MERGERS & ACQUISITIONS
6.3 AGREEMENTS, COLLABORATIONS, JOINT VENTURES & PARTNERSHIPS
6.4 NEW PRODUCT LAUNCH
6.5 OTHER DEVELOPMENTS
7 COMPANY PROFILES (OVERVIEW, FINANCIALS, PRODUCTS & SERVICES, STRATEGY, & DEVELOPMENTS)
7.1 3M COMPANY
7.2 ALKERMES, INC.
7.3 APTALIS PHARMA, INC.
7.4 BAXTER INTERNATIONAL, INC.
7.5 BECTON, DICKINSON AND COMPANY
7.6 CATALENT PHARMA SOLUTIONS
7.7 CIMA LABS
7.8 DALI MEDICAL DEVICES
7.9 ENDO HEALTH SOLUTIONS, INC.
7.10 FOAMIX
7.11 JOHNSON & JOHNSON, INC.
7.12 NEKTAR THERAPEUTICS, INC.
7.13 OPTINOSE AS
7.14 PSIVIDA CORPORATION
7.15 SKYEPHARMA PLC
7.16 TAPEMARK
7.17 THE DOW CHEMICAL COMPANY
7.18 VALEANT PHARMACEUTICALS
7.19 YPSOMED HOLDING AG (Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.)
LIST OF TABLES
TABLE 1 GLOBAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($BILLION)
TABLE 2 KEY DRUG DELIVERY TECHNOLOGY PROVIDERS & MARKETER COMPANIES
TABLE 3 GLOBAL ORAL DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 – 2017 ($BILLION)
TABLE 4 ORAL DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 5 CONTROLLED RELEASE DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 6 ODT & TASTE-MASKING MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 7 OTHER ORAL DRUG DELIVERY TECHNOLOGIES MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 8 GLOBAL PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 – 2017 ($BILLION)
TABLE 9 PULMONARY DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 10 COMPARATIVE OVERVIEW OF PULMONARY DRUG DELIVERY DEVICES
TABLE 11 METERED DOSE INHALATION MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 12 DRY POWDER INHALATION MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 13 NEBULIZERS MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 14 GLOBAL TRANSDERMAL DRUG DELIVERY MARKET, BY MODE OF DELIVERY, 2010 – 2017 ($BILLION)
TABLE 15 TRANSDERMAL DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 16 PASSIVE TRANSDERMAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2010 – 2017 ($BILLION)
TABLE 17 PASSIVE TRANSDERMAL DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 18 ACTIVE TRANSDERMAL DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 19 ACTIVE TRANSDERMAL DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 20 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2010 – 2017 ($BILLION)
TABLE 21 INJECTABLE DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 22 CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2010 – 2017 ($BILLION)
TABLE 23 CONVENTIONAL INJECTION DEVICES MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 24 GLOBAL SELF-INJECTION DEVICES MARKET, BY PRODUCT, 2010 – 2017 ($MILLION)
TABLE 25 SELF-INJECTION DEVICES MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 26 OTHER INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 27 GLOBAL OCULAR DRUG DELIVERY MARKET, BY FORMULATION, 2010 – 2017 ($BILLION)
TABLE 28 OCULAR DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 29 EYE DROP DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 30 OINTMENT & GEL DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 31 OTHER OCULAR DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 32 GLOBAL NASAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 – 2017 ($BILLION)
TABLE 33 NASAL DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 34 NASAL SPRAY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 35 NASAL INHALER MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 36 NASAL DROPS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 37 OTHER NASAL DELIVERY FORMULATIONS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 38 GLOBAL TOPICAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 – 2017 ($BILLION)
TABLE 39 TOPICAL DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 40 SEMI-SOLID TOPICAL FORMULATION MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 41 LIQUID TOPICAL FORMULATION MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 42 SOLID TOPICAL FORMULATION MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 43 GLOBAL IMPLANTABLE DRUG DELIVERY MARKET, BY DEVICE, 2010 – 2017 ($BILLION)
TABLE 44 IMPLANTABLE DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 45 DRUG-ELUTING STENTS MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 46 IMPLANTABLE INFUSION PUMPS MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 47 CONTRACEPTIVE IMPLANTS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 48 INTRAVITREAL IMPLANTS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 49 BRACHYTHERAPY SEEDS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 50 GLOBAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY MUCOSA TYPE, 2010 – 2017 ($BILLION)
TABLE 51 GLOBAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 52 ORAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 53 OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 54 DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 55 NORTH AMERICA: DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($BILLION)
TABLE 56 NORTH AMERICA: ORAL DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 – 2017 ($BILLION)
TABLE 57 NORTH AMERICA: PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 – 2017 ($BILLION)
TABLE 58 NORTH AMERICA: TRANSDERMAL DRUG DELIVERY MARKET, BY MODE OF DELIVERY, 2010 – 2017 ($BILLION)
TABLE 59 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 – 2017 ($BILLION)
TABLE 60 NORTH AMERICA: OCULAR DRUG DELIVERY MARKET, BY FORMULATION, 2010 – 2017 ($BILLION)
TABLE 61 NORTH AMERICA: NASAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 – 2017 ($BILLION)
TABLE 62 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 – 2017 ($MILLION)
TABLE 63 NORTH AMERICA: IMPLANTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 – 2017 ($MILLION)
TABLE 64 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY MUCOSA TYPE, 2010 – 2017 ($MILLION)
TABLE 65 EUROPE: DRUG DELIVERY TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($BILLION)
TABLE 66 EUROPE: ORAL DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 – 2017 ($BILLION)
TABLE 67 EUROPE: PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 – 2017 ($BILLION)
TABLE 68 EUROPE: TRANSDERMAL DRUG DELIVERY MARKET, BY MODE OF DELIVERY, 2010 – 2017 ($BILLION)
TABLE 69 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 70 EUROPE: OCULAR DRUG DELIVERY MARKET, BY FORMULATION, 2010 – 2017 ($MILLION)
TABLE 71 EUROPE: NASAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 – 2017 ($MILLION)
TABLE 72 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 – 2017 ($MILLION)
TABLE 73 EUROPE: IMPLANTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 – 2017 ($MILLION)
TABLE 74 EUROPE: TRANSMUCOSAL DRUG DELIVERY MARKET, BY MUCOSA TYPE, 2010 – 2017 ($MILLION)
TABLE 75 ASIA: DRUG DELIVERY TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($BILLION)
TABLE 76 ASIA: ORAL DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 – 2017 ($BILLION)
TABLE 77 ASIA: PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 – 2017 ($BILLION)
TABLE 78 ASIA: TRANSDERMAL DRUG DELIVERY MARKET, BY MODE OF DELIVERY, 2010 – 2017 ($BILLION)
TABLE 79 ASIA: INJECTABLE DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 80 ASIA: OCULAR DRUG DELIVERY MARKET, BY FORMULATION, 2010 – 2017 ($MILLION)
TABLE 81 ASIA: NASAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 – 2017 ($MILLION)
TABLE 82 ASIA: TOPICAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 – 2017 ($MILLION)
TABLE 83 ASIA: IMPLANTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 – 2017 ($MILLION)
TABLE 84 ASIA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY MUCOSA TYPE, 2010 – 2017 ($MILLION)
TABLE 85 ROW: DRUG DELIVERY TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($BILLION)
TABLE 86 ROW: ORAL DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 – 2017 ($BILLION)
TABLE 87 ROW: PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 – 2017 ($BILLION)
TABLE 88 ROW: TRANSDERMAL DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 89 ROW: INJECTABLE DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 90 ROW: OCULAR DRUG DELIVERY MARKET, BY FORMULATION, 2010 – 2017 ($MILLION)
TABLE 91 ROW: NASAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 – 2017 ($MILLION)
TABLE 92 ROW: TOPICAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 – 2017 ($MILLION)
TABLE 93 ROW: IMPLANTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 – 2017 ($MILLION)
TABLE 94 ROW: TRANSMUCOSAL DRUG DELIVERY MARKET, BY MUCOSA TYPE, 2010 – 2017 ($MILLION)
TABLE 95 MERGERS & ACQUISITIONS, 2011 –2013
TABLE 96 AGREEMENTS, COLLABORATIONS, JOINT VENTURES & PARTNERSHIPS, 2011 –2013
TABLE 97 NEW PRODUCT LAUNCH, 2010 – 2012
TABLE 98 OTHER DEVELOPMENTS, 2010 – 2013
TABLE 99 3M COMPANY: TOTAL REVENUE, BY SEGMENT, 2009 – 2011 ($MILLION)
TABLE 100 3M COMPANY: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)
TABLE 101 ALKERMES: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)
TABLE 102 BAXTER INTERNATIONAL: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION)
TABLE 103 BAXTER INTERNATIONAL: MEDICAL PRODUCTS TOTAL REVENUE, 2010 – 2012($MILLION)
TABLE 104 BAXTER INTERNATIONAL: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION)
TABLE 105 BECTON, DICKINSON: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION)
TABLE 106 BECTON, DICKINSON: MEDICAL DIVISION TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION)
TABLE 107 BECTON, DICKINSON: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012($MILLION)
TABLE 108 CATALENT PHARMA SOLUTIONS: TOTAL REVENUE, BY SEGMENT, 2009 – 2011 ($MILLION)
TABLE 109 TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION)
TABLE 110 TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION)
TABLE 111 ENDO HEALTH SOLUTIONS, INC.: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION)
TABLE 112 JOHNSON & JOHNSON, INC.: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION)
TABLE 113 JOHNSON & JOHNSON, INC.: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION)
TABLE 114 THE DOW CHEMICAL COMPANY: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION)
TABLE 115 VALEANT PHARMACEUTICALS: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION)
TABLE 116 YPSOMED: TOTAL REVENUE, BY SEGMENT, 2009 – 2011 ($MILLION)
TABLE 117 YPSOMED: TOTAL REVENUE, BY GEOGRAPHY, 2009 ($MILLION)
TABLE 118 YPSOMED: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2011 ($MILLION)
TABLE 1 GLOBAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($BILLION)
TABLE 2 KEY DRUG DELIVERY TECHNOLOGY PROVIDERS & MARKETER COMPANIES
TABLE 3 GLOBAL ORAL DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 – 2017 ($BILLION)
TABLE 4 ORAL DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 5 CONTROLLED RELEASE DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 6 ODT & TASTE-MASKING MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 7 OTHER ORAL DRUG DELIVERY TECHNOLOGIES MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 8 GLOBAL PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 – 2017 ($BILLION)
TABLE 9 PULMONARY DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 10 COMPARATIVE OVERVIEW OF PULMONARY DRUG DELIVERY DEVICES
TABLE 11 METERED DOSE INHALATION MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 12 DRY POWDER INHALATION MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 13 NEBULIZERS MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 14 GLOBAL TRANSDERMAL DRUG DELIVERY MARKET, BY MODE OF DELIVERY, 2010 – 2017 ($BILLION)
TABLE 15 TRANSDERMAL DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 16 PASSIVE TRANSDERMAL DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2010 – 2017 ($BILLION)
TABLE 17 PASSIVE TRANSDERMAL DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 18 ACTIVE TRANSDERMAL DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 19 ACTIVE TRANSDERMAL DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 20 GLOBAL INJECTABLE DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2010 – 2017 ($BILLION)
TABLE 21 INJECTABLE DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 22 CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2010 – 2017 ($BILLION)
TABLE 23 CONVENTIONAL INJECTION DEVICES MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 24 GLOBAL SELF-INJECTION DEVICES MARKET, BY PRODUCT, 2010 – 2017 ($MILLION)
TABLE 25 SELF-INJECTION DEVICES MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 26 OTHER INJECTORS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 27 GLOBAL OCULAR DRUG DELIVERY MARKET, BY FORMULATION, 2010 – 2017 ($BILLION)
TABLE 28 OCULAR DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 29 EYE DROP DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 30 OINTMENT & GEL DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 31 OTHER OCULAR DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 32 GLOBAL NASAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 – 2017 ($BILLION)
TABLE 33 NASAL DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 34 NASAL SPRAY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 35 NASAL INHALER MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 36 NASAL DROPS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 37 OTHER NASAL DELIVERY FORMULATIONS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 38 GLOBAL TOPICAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 – 2017 ($BILLION)
TABLE 39 TOPICAL DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 40 SEMI-SOLID TOPICAL FORMULATION MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 41 LIQUID TOPICAL FORMULATION MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 42 SOLID TOPICAL FORMULATION MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 43 GLOBAL IMPLANTABLE DRUG DELIVERY MARKET, BY DEVICE, 2010 – 2017 ($BILLION)
TABLE 44 IMPLANTABLE DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 45 DRUG-ELUTING STENTS MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 46 IMPLANTABLE INFUSION PUMPS MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 47 CONTRACEPTIVE IMPLANTS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 48 INTRAVITREAL IMPLANTS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 49 BRACHYTHERAPY SEEDS MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 50 GLOBAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY MUCOSA TYPE, 2010 – 2017 ($BILLION)
TABLE 51 GLOBAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 52 ORAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 53 OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES MARKET, BY GEOGRAPHY, 2010 – 2017 ($MILLION)
TABLE 54 DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
TABLE 55 NORTH AMERICA: DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($BILLION)
TABLE 56 NORTH AMERICA: ORAL DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 – 2017 ($BILLION)
TABLE 57 NORTH AMERICA: PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 – 2017 ($BILLION)
TABLE 58 NORTH AMERICA: TRANSDERMAL DRUG DELIVERY MARKET, BY MODE OF DELIVERY, 2010 – 2017 ($BILLION)
TABLE 59 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 – 2017 ($BILLION)
TABLE 60 NORTH AMERICA: OCULAR DRUG DELIVERY MARKET, BY FORMULATION, 2010 – 2017 ($BILLION)
TABLE 61 NORTH AMERICA: NASAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 – 2017 ($BILLION)
TABLE 62 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 – 2017 ($MILLION)
TABLE 63 NORTH AMERICA: IMPLANTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 – 2017 ($MILLION)
TABLE 64 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY MUCOSA TYPE, 2010 – 2017 ($MILLION)
TABLE 65 EUROPE: DRUG DELIVERY TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($BILLION)
TABLE 66 EUROPE: ORAL DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 – 2017 ($BILLION)
TABLE 67 EUROPE: PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 – 2017 ($BILLION)
TABLE 68 EUROPE: TRANSDERMAL DRUG DELIVERY MARKET, BY MODE OF DELIVERY, 2010 – 2017 ($BILLION)
TABLE 69 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 70 EUROPE: OCULAR DRUG DELIVERY MARKET, BY FORMULATION, 2010 – 2017 ($MILLION)
TABLE 71 EUROPE: NASAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 – 2017 ($MILLION)
TABLE 72 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 – 2017 ($MILLION)
TABLE 73 EUROPE: IMPLANTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 – 2017 ($MILLION)
TABLE 74 EUROPE: TRANSMUCOSAL DRUG DELIVERY MARKET, BY MUCOSA TYPE, 2010 – 2017 ($MILLION)
TABLE 75 ASIA: DRUG DELIVERY TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($BILLION)
TABLE 76 ASIA: ORAL DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 – 2017 ($BILLION)
TABLE 77 ASIA: PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 – 2017 ($BILLION)
TABLE 78 ASIA: TRANSDERMAL DRUG DELIVERY MARKET, BY MODE OF DELIVERY, 2010 – 2017 ($BILLION)
TABLE 79 ASIA: INJECTABLE DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 80 ASIA: OCULAR DRUG DELIVERY MARKET, BY FORMULATION, 2010 – 2017 ($MILLION)
TABLE 81 ASIA: NASAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 – 2017 ($MILLION)
TABLE 82 ASIA: TOPICAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 – 2017 ($MILLION)
TABLE 83 ASIA: IMPLANTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 – 2017 ($MILLION)
TABLE 84 ASIA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY MUCOSA TYPE, 2010 – 2017 ($MILLION)
TABLE 85 ROW: DRUG DELIVERY TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($BILLION)
TABLE 86 ROW: ORAL DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 – 2017 ($BILLION)
TABLE 87 ROW: PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 – 2017 ($BILLION)
TABLE 88 ROW: TRANSDERMAL DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 89 ROW: INJECTABLE DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 – 2017 ($MILLION)
TABLE 90 ROW: OCULAR DRUG DELIVERY MARKET, BY FORMULATION, 2010 – 2017 ($MILLION)
TABLE 91 ROW: NASAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 – 2017 ($MILLION)
TABLE 92 ROW: TOPICAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 – 2017 ($MILLION)
TABLE 93 ROW: IMPLANTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 – 2017 ($MILLION)
TABLE 94 ROW: TRANSMUCOSAL DRUG DELIVERY MARKET, BY MUCOSA TYPE, 2010 – 2017 ($MILLION)
TABLE 95 MERGERS & ACQUISITIONS, 2011 –2013
TABLE 96 AGREEMENTS, COLLABORATIONS, JOINT VENTURES & PARTNERSHIPS, 2011 –2013
TABLE 97 NEW PRODUCT LAUNCH, 2010 – 2012
TABLE 98 OTHER DEVELOPMENTS, 2010 – 2013
TABLE 99 3M COMPANY: TOTAL REVENUE, BY SEGMENT, 2009 – 2011 ($MILLION)
TABLE 100 3M COMPANY: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)
TABLE 101 ALKERMES: TOTAL REVENUE, BY GEOGRAPHY, 2009 – 2011 ($MILLION)
TABLE 102 BAXTER INTERNATIONAL: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION)
TABLE 103 BAXTER INTERNATIONAL: MEDICAL PRODUCTS TOTAL REVENUE, 2010 – 2012($MILLION)
TABLE 104 BAXTER INTERNATIONAL: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION)
TABLE 105 BECTON, DICKINSON: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION)
TABLE 106 BECTON, DICKINSON: MEDICAL DIVISION TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION)
TABLE 107 BECTON, DICKINSON: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012($MILLION)
TABLE 108 CATALENT PHARMA SOLUTIONS: TOTAL REVENUE, BY SEGMENT, 2009 – 2011 ($MILLION)
TABLE 109 TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION)
TABLE 110 TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION)
TABLE 111 ENDO HEALTH SOLUTIONS, INC.: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION)
TABLE 112 JOHNSON & JOHNSON, INC.: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION)
TABLE 113 JOHNSON & JOHNSON, INC.: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION)
TABLE 114 THE DOW CHEMICAL COMPANY: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION)
TABLE 115 VALEANT PHARMACEUTICALS: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2012 ($MILLION)
TABLE 116 YPSOMED: TOTAL REVENUE, BY SEGMENT, 2009 – 2011 ($MILLION)
TABLE 117 YPSOMED: TOTAL REVENUE, BY GEOGRAPHY, 2009 ($MILLION)
TABLE 118 YPSOMED: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2011 ($MILLION)
LIST OF FIGURES
FIGURE 1 GLOBAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION (2012)
FIGURE 2 DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
FIGURE 3 GLOBAL DRUG DELIVERY MARKET SEGMENTATION
FIGURE 4 MARKET DYNAMICS
FIGURE 5 PORTER’S FIVE FORCES ANALYSIS FOR DRUG DELIVERY MARKET
FIGURE 6 VALUE CHAIN ANALYSIS
FIGURE 7 GLOBAL PULMONARY DRUG DELIVERY: MARKET SHARE ANALYSIS, BY KEY PLAYER, 2012
FIGURE 8 GLOBAL TRANSDERMAL DRUG DELIVERY: MARKET SHARE ANALYSIS, BY KEY PLAYER, 2012
FIGURE 9 GLOBAL CONVENTIONAL INJECTION DEVICES: MARKET SHARE ANALYSIS, BY KEY PLAYER, 2012
FIGURE 10 GLOBAL SELF-INJECTION DEVICES: MARKET SHARE ANALYSIS, BY KEY PLAYER, 2012
FIGURE 11 GLOBAL IMPLANTABLE DRUG DELIVERY: MARKET SHARE ANALYSIS, BY KEY PLAYER, 2012
FIGURE 12 OPPORTUNITY MATRIX: GLOBAL DRUG DELIVERY MARKET (2012)
FIGURE 13 ORAL DRUG DELIVERY MARKET SHARE (2012)
FIGURE 14 KEY GROWTH STRATEGIES, 2010 – 2013
FIGURE 15 3M COMPANY: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)
FIGURE 16 ALKERMES: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011 ($MILLION)
FIGURE 17 APTALIS PHARMA, INC.: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)
FIGURE 18 BAXTER INTERNATIONAL: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($MILLION)
FIGURE 19 BECTON, DICKINSON: TOTAL REVENUE AND R&D EXPENDITURE, 2010 – 2012 ($MILLION)
FIGURE 20 CATALENT PHARMA SOLUTIONS: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)
FIGURE 21 TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($MILLION)
FIGURE 22 ENDO HEALTH SOLUTIONS, INC.: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($MILLION)
FIGURE 23 JOHNSON & JOHNSON, INC.: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($MILLION)
FIGURE 24 NEKTAR THERAPEUTICS, INC.: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)
FIGURE 25 PSIVIDA CORPORATION: TOTAL REVENUE, 2009 – 2011 ($MILLION)
FIGURE 26 SKYEPHARMA PLC: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)
FIGURE 27 THE DOW CHEMICAL COMPANY: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($MILLION)
FIGURE 28 VALEANT PHARMACEUTICALS: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($MILLION)
FIGURE 29 YPSOMED: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)
FIGURE 1 GLOBAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION (2012)
FIGURE 2 DRUG DELIVERY MARKET, BY GEOGRAPHY, 2010 – 2017 ($BILLION)
FIGURE 3 GLOBAL DRUG DELIVERY MARKET SEGMENTATION
FIGURE 4 MARKET DYNAMICS
FIGURE 5 PORTER’S FIVE FORCES ANALYSIS FOR DRUG DELIVERY MARKET
FIGURE 6 VALUE CHAIN ANALYSIS
FIGURE 7 GLOBAL PULMONARY DRUG DELIVERY: MARKET SHARE ANALYSIS, BY KEY PLAYER, 2012
FIGURE 8 GLOBAL TRANSDERMAL DRUG DELIVERY: MARKET SHARE ANALYSIS, BY KEY PLAYER, 2012
FIGURE 9 GLOBAL CONVENTIONAL INJECTION DEVICES: MARKET SHARE ANALYSIS, BY KEY PLAYER, 2012
FIGURE 10 GLOBAL SELF-INJECTION DEVICES: MARKET SHARE ANALYSIS, BY KEY PLAYER, 2012
FIGURE 11 GLOBAL IMPLANTABLE DRUG DELIVERY: MARKET SHARE ANALYSIS, BY KEY PLAYER, 2012
FIGURE 12 OPPORTUNITY MATRIX: GLOBAL DRUG DELIVERY MARKET (2012)
FIGURE 13 ORAL DRUG DELIVERY MARKET SHARE (2012)
FIGURE 14 KEY GROWTH STRATEGIES, 2010 – 2013
FIGURE 15 3M COMPANY: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)
FIGURE 16 ALKERMES: TOTAL REVENUE AND R&D EXPENDITURE, 2009 – 2011 ($MILLION)
FIGURE 17 APTALIS PHARMA, INC.: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)
FIGURE 18 BAXTER INTERNATIONAL: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($MILLION)
FIGURE 19 BECTON, DICKINSON: TOTAL REVENUE AND R&D EXPENDITURE, 2010 – 2012 ($MILLION)
FIGURE 20 CATALENT PHARMA SOLUTIONS: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)
FIGURE 21 TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($MILLION)
FIGURE 22 ENDO HEALTH SOLUTIONS, INC.: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($MILLION)
FIGURE 23 JOHNSON & JOHNSON, INC.: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($MILLION)
FIGURE 24 NEKTAR THERAPEUTICS, INC.: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)
FIGURE 25 PSIVIDA CORPORATION: TOTAL REVENUE, 2009 – 2011 ($MILLION)
FIGURE 26 SKYEPHARMA PLC: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)
FIGURE 27 THE DOW CHEMICAL COMPANY: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($MILLION)
FIGURE 28 VALEANT PHARMACEUTICALS: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($MILLION)
FIGURE 29 YPSOMED: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION)
